Bank of Montreal Can acquired a new stake in shares of Icosavax, Inc. (NASDAQ:ICVX – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,876 shares of the company’s stock, valued at approximately $310,000. Bank of Montreal Can owned 0.07% of Icosavax at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Icosavax by 82.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,342,470 shares of the company’s stock worth $19,152,000 after acquiring an additional 1,506,613 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Icosavax by 34.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,463,525 shares of the company’s stock worth $35,441,000 after acquiring an additional 1,148,465 shares in the last quarter. FMR LLC increased its position in shares of Icosavax by 22.9% during the first quarter. FMR LLC now owns 6,003,002 shares of the company’s stock worth $34,817,000 after acquiring an additional 1,117,631 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Icosavax by 51.6% during the first quarter. Vanguard Group Inc. now owns 863,933 shares of the company’s stock worth $6,081,000 after acquiring an additional 294,065 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its position in shares of Icosavax by 8.9% during the first quarter. Platinum Investment Management Ltd. now owns 2,449,902 shares of the company’s stock worth $14,209,000 after acquiring an additional 200,191 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.
Icosavax Stock Performance
Shares of ICVX stock opened at $10.75 on Tuesday. Icosavax, Inc. has a 52-week low of $2.61 and a 52-week high of $16.45. The company has a 50-day simple moving average of $7.35 and a two-hundred day simple moving average of $8.28. The company has a market capitalization of $538.47 million, a price-to-earnings ratio of -4.84 and a beta of 0.45.
Analyst Upgrades and Downgrades
Icosavax Company Profile
Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
- Five stocks we like better than Icosavax
- Do ETFs Pay Dividends? What You Need to Know
- The most upgraded stocks in November have two things in common
- 3 Small Caps With Big Return Potential
- Monday.com rocked earnings like it’s the weekend
- Your Comprehensive Guide to Investing in Bank Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.